Author

Damian Szatkowski

Observed names: D Szatkowski, D. Szatkowski, Damian L Szatkowski, Damian L. Szatkowski, Szatkowski, D, Szatkowski, Damian, Szatkowski, Damian L.

Institution: Helse Førde

Observed institutions: Oslo University Hospital, University of Bradford, Helse Førde, Gdańsk Medical University

ORCID: 0009-0008-9212-9595

Observed ORCID: 0009-0008-9212-9595

OpenAlex ID: A5033356638

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

2016 · Sonja Zweegman, Bronno van der Holt, et al. · Blood · 124

α-Melanocyte-Stimulating Hormone Modulates Nitric Oxide Production in Melanocytes1

2000 · Alison Graham, Philip Manning, et al. · Journal of Investigative Dermatology · 58

Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript

2006 · K Halaburda, W Prejzner, et al. · Bone Marrow Transplantation · 46

Imatinib therapy prior to myeloablative allogeneic stem cell transplantation

2005 · J M Zaucha, W Prejzner, et al. · Bone Marrow Transplantation · 43

Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study

2019 · Lene Kongsgaard Nielsen, Claudia Stege, et al. · Haematologica · 32

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial

2020 · Sonja Zweegman, Claudia A.M. Stege, et al. · Haematologica · 28

Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Results from the Randomized Phase II HOVON-126/Nmsg 21#13 Trial

2018 · Sonja Zweegman, Fredrik H. Schjesvold, et al. · Blood · 11

The Overexpression of KIT Proto-Oncogene in Acute Leukemic Cells Is Not Necessarily Caused by the Gene Mutation

2014 · Damian Szatkowski, Andrzej Hellmann · Acta Haematologica · 9

Randomized Phase III Trial in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma Comparing Melphalan-Prednisone-Thalidomide Followed By Thalidomide Maintenance (MPT-T) Versus Melphalan-Prednisone-Lenalidomide Followed By Maintenance with Lenalidomide (MPR-R); A Joint Study of the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and the Nordic Myeloma Study Group (NMSG)

2014 · Sonja Zweegman, Bronno van der Holt, et al. · Blood · 7

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group

2024 · Anu Partanen, Anders Waage, et al. · Cancers · 5

A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

2020 · Raija Helena Silvennoinen, Anders Waage, et al. · Blood · 5

Monoclonal gammopathy of undetermined significance and anti-TNF-α treatment: comments on the article by Smale and Lawson

2013 · P Mielnik, AM Hjelle, et al. · Scandinavian Journal of Rheumatology · 5

Frailty Predicts Survival and Toxicity in Newly Diagnosed Multiple Myeloma Patients Ineligible for Autologous Stem Cell Transplantation; Report of the HOVON-87/Nmsg-18 Study Group

2017 · Claudia A.M. Stege, Bronno van der Holt, et al. · Pure Amsterdam UMC · 4

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13

2023 · Kazimierz Groen, Fredrik H. Schjesvold, et al. · HemaSphere · 3

Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma

2025 · Frida Bugge Askeland, Vilhelm Hauge Bugge, et al. · Blood Cancer Journal · 1

Quality of Life With Melphalan/ Prednisone Plus Either Thalidomide (mpt-t) or Lenalidomide (mpr-r) in Non-transplant Eligible Newly Diagnosed Multiple Myeloma; Results of the Hovon87/nmsg18 Study

2017 · Stege, Claudia A.M., Kongsgaard Nielsen, Lene; id_orcid 0000-0003-2083-3870, et al. · University of Southern Denmark Research Portal (University of Southern Denmark) · 1

Health-related quality of life in non-transplant eligible newly diagnosed multiple myeloma patients treated with melphalan/prednisolone plus either thalidomide or lenalidomide; results of the HOVON87/NMSG18 study

2017 · Nielsen, Lk, Stege, C, et al. · Pure Amsterdam UMC · 1

Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Initial Results from the Randomized Phase II HOVON-126/Nmsg 21.13 Trial

2017 · Zweegman, Sonja, van der Holt, Bruno, et al. · University of Southern Denmark Research Portal (University of Southern Denmark) · 1

PA-272 Ixazomib, Lenalidomide, Dexamethasone Treatment With Cytogenetic Risk-Based Maintenance in Transplant-Eligible Multiple Myeloma Patients: The Expanded Results of a Phase 2 Study

2026 · Raija Silvennoinen, Anu Partanen, et al. · Clinical Lymphoma Myeloma & Leukemia

MRD-Negative Response After VRd induction, HD-ASCT, and VRd consolidation in Transplant-Eligible Newly Diagnosed Multiple Myeloma: Phase 2 REMNANT Study with Broad Inclusion Criteria

2026 · Frida Bugge Askeland, Anne-Marie Rasmussen, et al. · Research Square

Optimizing lenalidomide therapy in renal impairment: Analysis of renal response in the prospective remnant study in transplant-eligible newly diagnosed multiple myeloma

2025 · Frida Bugge Askeland, Vilhelm Hauge Bugge, et al. · Blood

Selinexor with Alternating Bortezomib or Lenalidomide Plus Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients (SABLe), Nordic Myeloma Study Group 29/21

2024 · Ida Bruun Bruun Kristensen, Hanne Marie Norseth, et al. · Blood

P898: a Prospective Phase 2 Study to Assess Minimal Residual Disease After Ixazomib, Lenalidomide, Dexamethasone (ird) Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

2023 · Raija Silvennoinen, Anu Partanen, et al. · HemaSphere

P-222: A prospective phase 2 study to assess minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients

2022 · Raija Silvennoinen, Anders Waage, et al. · Clinical Lymphoma Myeloma & Leukemia

P905: Ixazomib-thalidomide-dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Non-transplant Eligible Newly Diagnosed Multiple Myeloma Patients; Long-term Results of Hovon-126/nmsg 21.13

2022 · K. Groen, M. R. Seefat, et al. · HemaSphere

Works count: 30

Citation count: 384

H-index: 8

I10-index: 7